HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $8.
HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $8.
